New Target for the Treatment of Abdominal Obesity

Summary of the technology

New target for the treatment of obesity and abdominal obesity by inhibiting the FGFR3 receptor signalling pathway
Project ID : 7-2018-4658

Details of the Technology Offer

Background

Obesity is the leading cause of death in America, and is associated with an increase in chronic diseases like, cardiovascular diseases, hypertension, and metabolic disease involving the liver as well as type 2 diabetes. A recent study has shown a correlation between an overexpression of a specific protein and abdominal obesity, however no follow up studies were carried out to indicate a treatment.

Our Innovation

The researcher has identified several inhibitory small molecules that specifically target the overexpressed protein responsible for abdominal obesity. A small molecule therapy would inhibit the proteins and reduce or prevent abdominal obesity.

Opportunity

The researcher is looking for sponsored research funding from a partner to:

  • Identify the best small molecule for inhibiting the overexpressed proteins.
  • Conduct an in vitro study to elucidate the influence of the small molecule on signaling pathways responsible for abdominal obesity.
  • Conduct an in vivo study developed in the researcher’s lab to see the influences of the small molecule on the model animal.
  • Conduct an analysis of the carcass of the model animals.

Project manager

Ilya Pittel
VP, BD AGTECH, FOODTECH, VETERINARY & ENVIRONMENT

Project researchers

Efrat Monsonego-Ornan
HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences
Biochemistry, Food Science and Nutrition

Related Keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Yissum - Research Development Company of the Hebrew University

Never miss an update from Yissum - Research Development Company of the Hebrew University

Create your free account to connect with Yissum - Research Development Company of the Hebrew University and thousands of other innovative organizations and professionals worldwide

Yissum - Research Development Company of the Hebrew University

Send a request for information
to Yissum - Research Development Company of the Hebrew University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support